Apogee Biotechnology Corporation
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Apogee Biotechnology Corporation
The Israel-based, NASDAQ-listed biotech tells Scrip that if the oral SK2 selective inhibitor succeeds in a Phase II/III study, it would be "very comfortable" taking opaganib all the way to market on its own.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Market Intel: Nanorobots, Digital Tracking, Dose Printing: Innovative Drug Delivery Systems Will Make Precise Drug Dosing A Reality
Precision medicine delivered by novel drug delivery systems, ranging from sensors to dose printers, could eventually revolutionize the pharmaceutical industry. Although many of these technologies are years away from commercialization, their ability to provide exact dosing with slow sustained release and more targeted therapy should improve patient compliance and outcomes.